{"entity":{"id":"nct06589830","kind":"trial","name":"TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer","aka":[],"tldr":"A phase 2 trial of Trastuzumab in colorectal cancer, run by Suzhou Teligene Ltd., now recruiting.","summary":"TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer is a phase 2 interventional study registered as NCT06589830 by Suzhou Teligene Ltd., with 80 participants planned, started 2025-05-13 and due to reach its primary completion in 2026-10. Interventions recorded: TL938 Capsules, Trastuzumab. Conditions listed: Colorectal Cancer Metastatic, Advanced Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06589830","url":"https://clinicaltrials.gov/study/NCT06589830"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06589830","phase":"2","setting":"A Phase 2 Study to Evaluate TL938 Combined With Trastuzumab in Patients With HER2-positive Metastatic Colorectal Cancer","sponsor":"Suzhou Teligene Ltd.","enrolled":80,"outcomes":[]},"route":"/trials/nct06589830/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}]}}